Yescarta first CAR-T drug to show high response rates and durable benefit in iNHL

7 December 2020
gilead-big

Gilead Sciences (Nasdaq: GILD) company Kite has announced results from the primary analysis of ZUMA-5, a Phase II study evaluating Yescarta (axicabtagene ciloleucel) in adults with relapsed/refractory indolent non-Hodgkin lymphoma (iNHL) after at least two prior lines of therapy.

After a single infusion of Yescarta, 92% of iNHL patients responded, including 76% of patients achieving a complete response at a median follow-up of 17.5 months.

The data were presented in an oral session during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology